Low-Dose radiation plus immunotherapy shows promise for Tough-to-Treat nasopharyngeal cancer
NCT ID NCT07325539
First seen Jan 11, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This phase 2 trial is testing whether adding low-dose radiotherapy to a standard chemotherapy regimen plus the immunotherapy drug toripalimab can help people with recurrent or metastatic nasopharyngeal carcinoma. About 55 participants will receive the combination therapy in cycles. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGShenzhen, Guangdong, 518116, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose radiotherapy, toripalimab, gemcitabine, and cisplatin
What this could lead to
If successful, this combination could offer a new treatment option for people with recurrent or metastatic nasopharyngeal carcinoma, potentially slowing disease progression.
What could go wrong
This is an early-phase, single-arm trial with only 55 participants, so results may not apply broadly. Side effects from chemotherapy and immunotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.